Mediastinal shed blood Cardiopulmonary bypass surgery
INTRODUCTION
Despite recent advances in the understanding of the clinical hemostatic defect produced by cardiopulmonary bypass, postoperative bleeding following cardiac surgery remains a significant source of morbidity and increases the frequency of homologous blood transfusions. Postoperative reinfusion of shed mediastinal blood has been shown to reduce homologous blood requirement while not increasing postoperative blood loss after cardiac surgery [1, 2] .
The loss of platelet function is considered the most important defect in the hemostatic system caused by cardiopulmonary bypass resulting in blood loss [3] , and is manifested in vivo in humans in the postoperative period as a prolongation of the template bleeding time [4, 5] . The postoperative bleeding time has been shown to correlate with non-surgical blood loss following cardiopulmonary bypass [6] .
Transfusion of nonwashed shed mediastinal blood has been shown to increase the plasma level of fibrin degradation products in the recipient and, as such, may have potentially serious implications in the postoperative patient [7] .
Platelet aggregation may be inhibited by the products of fibrinogen and fibrin degradation by binding of these products to fibrinogen and platelet membrane glycoprotein Ilb/IIIa, thus interfering with the normal interaction between platelets and fibrinogen [8] . In addition, evidence from patients with acute myocardial infarction treated with tissue-type ■■^-"t^v^-^s&c *•.?....
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plasminogen activator indicates that there may be a plasminmediated derangement of platelet aggregation in vivo, demonstrated by a prolongation of the template bleeding time, that correlates with spontaneous bleeding complications after thrombolytic therapy [9] .
These data suggest two potential mechanisms of in vivo platelet dysfunction resulting from the transfusion of There was not one of the above criteria that ensured transfusion, but rather, a clinical decision was made based on the status of each patient.
Once the decision to transfuse was made, the intensive care unit nurse was instructed, based on the preoperative randomization, to give either the volume of mediastinal shed blood that had collected up to that point, or one unit of packed red blood cells. Autologous packed cells were used if available, otherwise, homologous packed cells were transfused. [10] . Serum creatinine levels were determined using a Beckman Astra 8 serum electrolyte analyzer (Beckman Instruments, Brea, CA).
Total protein and albumin levels were measured by the Biuret reactions method of Kingsley [11] . Factor V (% normal), Factor VIII clotting protein (% normal), and fibrinogen (mg/dl) levels were measured by clotting assays using blood collected in 3.8 % sodium citrate [12] .
Antithrombin III (% normal) was measured by a heparin cofactor assay with chromogenic substrate [13] . Protein C (% normal) was measured as described by Nicham, et al, using the chromogenic substrate CBS [14] . Fibronectin (/xg/ml) was measured by an immunoturbidometric assay [15] . Plasminogen activity (% normal) was measured using the chromogenic substrate S-2251 as described by Friberger [16] . In vivo activation of fibrinolysis (i.e., plasmin activation) was assessed indirectly by measuring consumption of plasma antiplasmin activity (% normal) as described by Gallimore, et al [17] . Fibrin degradation products (/ig/ml) were measured using a Trombowell-cotest Kit (Burroughs Wellcome Diagnostics, Greenville, NC) [18] . D-Dimer levels were measured by latex immunoassay using a monoclonal antibody as described by
Mirshahi et al [19] . Whole blood microaggregates (Swank, mm Hg/gm Hb) were assessed in blood collected in K 3 EDTA using a Procedures were performed for isolated coronary (n=23), valvular (n=4), and combined (n=5) disease. Patient characteristics are shown in Table 1 . There were no significant differences between Group 1 and Group 2 with ml, range 300-1700 ml. Table 2 Hematologic parameters. Table 3 shows the results for selected hematologic parameters measured during the study.
There were no significant differences in any of the parameters at baseline between Group 1 and Group 2. (Table 3) . Neither the hematocrit, nor the platelet count were significantly different between the two groups at any time point in the study. Likewise, cellular hemoglobin levels were not significantly different between Group 1 and Group 2 for the entire study ( Table 3 (Table 3) . White blood cell counts rose significantly (p < 0.05) in both groups on CPB from approximately 6,000/mm 3 preoperatively to 10-12,000/mm 3 at the end of CPB, and remained slightly elevated in both groups throughout the study. These counts were, however, never significantly different between the two groups throughout the study (Table 3) . Plasma microaggregate levels assessed by Plasma protein parameters. Table 4 shows the results for selected plasma protein parameters measured during the study.
There were no significant differences in any of the parameters at baseline between Group 1 and Group 2. (Table 4 ). Factor VIII clotting activity levels were never significantly different between the two groups at all timepoints throughout the study. Fibrinogen levels behaved similiar to Factor VIII levels by falling significantly (p < 0.05) on CPB, and then increasing postoperatively to levels above baseline (p < 0.05) by the second postoperative day in both groups. These levels remained elevated for the remainder of the study, but were never significantly different between the two groups at any timepoint throughout the study (Table 4) . Antithrombin III levels and fibronectin levels behaved in a similiar manner, again falling significantly (p < 0.05) with the initiation of CPB, and then gradually increasing in the postoperative period to preoperative levels by the seventh postoperative day in both groups. These levels were never significantly different between the two groups for the entire study (Table 4 ).
Protein C levels fell significantly in both groups (p < 0.05)
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on CPB (Group 1: 112 ± 7 % to 65 ± 5 %, Group 2: 102 ± 5 % to 67 ± 5 %). However, in contrast to the other proteins, the level of Protein C was significantly greater (p < 0.05) in Group 1 (72 ± 4 %) compared to Group 2 (63 ± 2 %) two hours after transfusion. These differences were no longer significant by the first postoperative day, and the level of Protein C remained below baseline in both groups until the seventh postoperative day (Table 4) . Except for Protein C, all measured plasma protein levels were not significantly changed by transfusion with either nonwashed shed mediastinal blood or liquid preserved packed cells during this study.
Bleeding time and fibrinolytic parameters. Table 5 shows the results for the bleeding time, not corrected for skin temperature, and plasma fibrinolytic parameters measured during the study. (Table 5) . Plasminogen levels were not significantly different at baseline between the two groups.
Plasminogen levels fell significantly (p < 0.05) in both groups with initiaion of CPB, and gradually rose in the postoperative period, returning to baseline levels by the seventh postoperative day. The plasminogen levels were never significantly different between the two groups at every timepoint during the study including two hours after transfusion (Table 5) . Plasma antiplasmin levels were significantly different (p < 0.05) at baseline between Group 1 (78 ± 3 %) and Group 2 (71 ± 2 %), probably representing an experimental population sampling error as opposed to any real intergroup difference. Antiplasmin levels decreased significantly (p < 0.05) in both groups with initiation of CPB, and remained significantly lower (p < 0.05) in Group 2 (45 ± 2 %) compared to Group 1 (57 ± 4) at the end of CPB.
The antiplasmin levels in both groups were unaffected by transfusion, and returned to preoperative levels by the second postoperative day at which point they were no longer significantly different from one another. Antiplasmin levels increased significantly (p < 0.05) in similiar fashion in both groups for the remainder of the study and were not significantly different between the two groups (Table 5 ).
Blood loss and blood product use. Table 6 shows the 
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The data from this study are consistent with data from 
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